All In Biotech

Free tool

FAERS Monitor: Mepsevii

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761047 or its brand name (Mepsevii, Vestronidase Alfa-Vjbk). Reports on generic versions are filed under their own applications.

Reports

64

Serious

35

55% of reports

Hospitalization

23

Death reported

6

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product dose omission issue5
  • vomiting5
  • cough4
  • rash4
  • fall3
  • pneumonia3
  • respiratory failure3
  • acute respiratory failure2
  • anaphylactic reaction2
  • contusion2
  • fatigue2
  • head injury2
  • infusion related reaction2
  • nasopharyngitis2
  • pulmonary embolism2

Reports by year received

View as table
YearReports
20186
201910
202011
20215
20223
20231
202410
202512
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,095 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acute respiratory failure234.28.736
head injury220.85.320
respiratory failureSignal313.54.523
anaphylactic reaction211.93.011
infusion related reaction29.92.58
pulmonary embolism26.91.85
contusion26.81.75
product dose omission issueSignal55.62.415
coughSignal44.71.88
nasopharyngitis23.60.92
vomitingSignal53.51.57
pneumonia33.01.02
rash43.01.24
fall33.01.02
fatigue20.80.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.